Nesfatin-1 Human ELISA

Regulatery Status: RUO
Type: Sandwich ELISA, Biotin-labelled antibody
Other Names Status: Nucleobindin-2, DNA-binding protein NEFA, Gastric cancer antigen Zg4, NUCB2, NEFA
Species: Human
Catalog No Size
Product Catalog No: RD191227200R Pack Size: 96 wells (1 kit)

Pack Size:
Pack Size:
Pack Size:
Pack Size:

Category:
Product Features

Nesfatin-1 was first described in 2006 as a neurohormone derived from the protein NEFA/nucleobindin2 (NUCB2). It is a polypeptide consisting of 82 amino acids, with high level of homology in human, mouse and rat. Nesfatin-1 has been localized in the brain, particulary in the nuclei of the hypothalamus, in the adipose tissue and the gastrointestinal tract, but also in serum and cerebrospinal fluid. Nesfatin-1 was identified as a satiety molecule affecting fat metabolism. Intracerebroven­tricular administration of nesfatin-1 induces decreases in food intake and body weight and increases in sympathetic nerve activity and mean arterial pressure. Effect of Nesfatin-1 is leptin – independent, it is probably mediated by melanocortin system. Several studies are currently focused on the possibility of using Nesfatin-1 in the treatment of obesity, even in individuals with leptin resistence. Due to the presence in serum Nesfatin-1 could also serve as a clinical marker in the diagnosis of many diseases. The important role of nesfatin-1 in metabolism of glucose and insulin has been reported in several studies. Different concentrations were observed in patients with diabetes mellitus type I. and II. In individuals with DM type II. postprandial concentration of nesfatin-1 was significantly lower than that of DM type I. and healthy subjects. Different levels of Nesfatin-1 was measured in patients with anorexia nervosa and panic disorders in comparison with a control healthy group. Data obtained in experiments with rat models indicate that nesfatin-1 acts as a peripheral modulator of the cardiac function. Much higher levels of serum Nesfatin-1 (up to 160×) were detected in patients with primarily diagnosed epilepsy. During the treatment with anti-epileptics concentration of Nesfatin-1 decreased, but it was still about 10 times higher that the level of the hormone in healthy individuals. It offers the idea that it would be possible to use the Nesfatin-1 as a marker for diagnosis and monitoring of epilepsy.

Features

  • It is intended for research use only
  • The total assay time is less than 4 hours
  • The kit measures human nesfatin-1 in serum, plasma (EDTA, citrate, heparin)
  • Assay format is 96 wells
  • Standard is recombinant (E.coli) protein based
  • Components of the kit are provided ready to use, concentrated or lyophilized

Research topic

Energy metabolism and body weight regulation, Neural tissue markers

Technical Sheet / Info

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma-EDTA, Plasma-Heparin, Plasma-Citrate

Sample Requirements

20 µl/well

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.125–4 ng/ml

Limit of Detection

0.021 ng/ml

Intra-assay (Within-Run)

n = 8; CV = 4.3%

Inter-assay (Run-to-Run)

n = 6; CV = 5.9%

Spiking Recovery

99,90%

Dilutation Linearity

107,90%

Order Enquiry

Order Enquiry Form

References

– Boutsikou T, Briana DD, Boutsikou M, Kafalidis G, Piatopoulou D, Baka S, Hassiakos D, Gourgiotis D, Malamitsi-Puchner A. Cord blood nesfatin-1 in large for gestational age pregnancies. Cytokine. 2013 Feb;61 (2):591-4

Enquiry